PLRX
Pliant TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
PLRX has a funded runway and an oncology reset centered on PLN-101095. Early response signals and first-patient dosing in FORTIFY provide a credible but highly preliminary path to rerating if expansion data confirm activity.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Early-stage oncology data may not replicate in FORTIFY or show durable benefit.
Momentum
96
Value
58
Sentiment
76
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.20 · Bull $2.50 · Bear $0.55
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $2.50
Why
Momentum96 · Δ7d -
Value58 · Δ7d -0.1
Sentiment76 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
96
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
76
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 95.7 / Value 57.8 / Sentiment 76.2
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$71.21M
Beta
1.39
Shares Out
61.92M
P/E (TTM) · Derived
-0.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.72
Rev YoY
-100.0%
EPS YoY
-64.7%
Gross Margin
-1160.5%
Op Margin
-
Net Debt
-$161.84M
Current Ratio
16.89
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology